In patients affected by chronic hepatitis C (CHC) infection, viral eradication can be achieved by antiviral therapy based on the use of a combination of pegylated interferon a-2a or 2b and ribavirin that yields a sustained eradication in 4050% of cases. The aim of this review is to evaluate the efficacy of pegylated interferon a-2a or a-2b plus ribavirin in the treatment of CHC infection. Treatment must be started in patients with detectable serum hepatitis C virus (HCV) RNA independently by serum alanine aminotransferase levels. In patients infected with genotype 1 or 4 HCV before treatment, a histological evaluation is required. These patients can be treated if stage is 2 according to the Knodell index. The treatment must be for 1 year duration and current guidelines allow treatment to be continued if patients remain HCV RNA positive at week 12 if a 2-log drop in viral load has been achieved. In patients with genotype 2 or 3 HCV, therapy must be prolonged for 6 months and histological evaluation pretreatment is not necessary.
Introduction
Hepatitis C virus (HCV) infects approximately 170 million individuals worldwide and chronic HCV infection has been estimated to be responsible for approximately 300,000 to 400,000 deaths per year, due to decompensation of cirrhosis, end-stage liver disease and hepatocellular carcinoma [Hoofnagle, 2002] . Acute HCV infection progresses to chronic infection in 70% of cases. Acute HCV infection is characterized by two fundamental aspects: (1) a high rate of progression to chronic hepatitis C (CHC) infection;
(2) the majority of patients are asymptomatic. Acute infection due to HCV results in a chronic progression in 5084% of cases. The risk is much lower in younger than in elderly individuals because they have a greater chance of spontaneous clearance of the virus. Spontaneous viral clearance occurs in the first 3 months of infection in 20% of asymptomatic patients and in 40% of symptomatic patients with acute HCV infection [Gerlach et al. 2003 ]. In light of the risk of developing chronic disease and the response rate to treatment once the disease is established, it is very important to consider early treatment of acute HCV infection before it progresses to the chronic form. Treatment of acute HCV infection is based on pegylated interferon (PEG-IFN) a-2b (Peg-Intron Õ ) or a-2a (Pegasys Õ ) monotherapy [Santantonio et al. 2005; Scotto et al. 2005 ]. In patients with CHC infection, viral eradication can be achieved by antiviral therapy based on the use of a combination of PEG-IFN a-2a or 2b and ribavirin, which yields a sustained eradication of infection in 4050% of cases [Fried et al. 2002; Manns et al. 2001] . The aim of this review is to evaluate the efficacy of PEG-IFN a-2a or a-2b in the treatment of CHC infection.
Pharmacodynamics and pharmacokinetics PEG-IFN a-2b is a covalent conjugate of recombinant a-2b IFN with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 Da. The average molecular weight of the PEG-IFN molecule is approximately 31,000 Da. IFN a-2b is a water-soluble protein with a molecular weight of 19,271 Da produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a strain of Escherichia coli bearing a genetically engineered plasmid containing an IFN gene from human leukocytes.
The biological activity of PEG-IFN a-2b is derived from its IFN a-2b moiety. Following a single subcutaneous dose of PEG-IFN a-2b, the mean absorption half life was 4.6 hours and maximal serum concentrations occur between 1544 hours postdose, and are sustained for up to 4872 hours. The maximal serum concentrations measurements of PEG-IFN a-2b increase in a dose-related manner. After multiple dosing, there is an increase in bioavailability of PEG-IFN a-2b. The mean PEG-IFN a-2b elimination half life is approximately 40 hours (range 2260 hours). Renal elimination accounts for 30% of the clearance. Pegylation of IFN a-2b produces a product whose clearance is lower than that of non-PEG-IFN a-2b. IFNs exert their cellular activities by binding to specific membrane receptors on the cell surface and initiate a complex sequence of intracellular events. The effects of IFNs include the induction of certain enzymes, suppression of cell proliferation, immunomodulating activities such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells, and inhibition of virus replication in virus-infected cells. PEG-IFN a-2b raises concentrations of effector proteins such as serum neopterin and 2 0 -5 0 -oligoadenylate synthetase, raises body temperature, and causes reversible decreases in leukocyte and platelet counts [Caliceti, 2004] .
Pegasys Õ , PEG-IFN a-2a, is a covalent conjugate of recombinant a-2a IFN (approximate molecular weight 20,000 Da) with a singlebranched bis-monomethoxy PEG chain (approximate molecular weight 40,000 Da). The PEG moiety is linked at a single site to the IFN a moiety via a stable amide bond to lysine. PEG-IFN a-2a has an approximate molecular weight of 60,000 Da. IFN a-2a is produced using recombinant DNA technology in which a cloned human leukocyte interferon gene is inserted into and expressed in E. coli. Maximal serum concentrations (C max ) and area under the curve (AUC) increased in a nonlinear doserelated manner following administration of 90270 mg Pegasys Õ . C max occurs between 7296 hours postdose. Week 48 mean trough concentrations (16 Zg/ml; range 428 Zg/ml) at 168 hours postdose are approximately twofold higher than week 1 mean trough concentrations (9 Zg/ml; range 015 Zg/ml). Steady-state serum levels are reached within 58 weeks of once-weekly dosing [Youngster et al. 2002] . Ribavirin is absorbed from the gastrointestinal tract probably by nucleoside transporters.
Absorption is about 45%, and this is increased modestly (to about 75%) by a fatty meal. Once in the plasma, ribavirin is transported through the cell membrane also by nucleoside transporters. Ribavirin is widely distributed in all tissues, including the cerebrospinal fluid (CSF) and brain. The pharmacokinetics of ribavirin is dominated by trapping of the phosphated form inside cells, particularly in red blood cells (RBCs) which lack the enzyme to remove the phosphate once it has been added by kinases, and therefore attain high concentrations of the drug. Most of the kinase activity, which converts the drug into an active nucleotide form, is provided by adenine kinase. This enzyme is more active in virally infected cells. The volume of distribution of ribavirin is large (2000 l/kg) and the length of time the drug is trapped varies greatly from tissue to tissue. The mean half life for multiple doses in the body is about 12 days, but very long-term kinetics are dominated by the kinetics of RBCs (half-life 40 days). RBCs store ribavirin for their lifetime, releasing it into body systems when old cells are degraded in the spleen. About a third of absorbed ribavirin is excreted in the urine unchanged, and the rest is excreted in urine as the deribosylated base, 1,2,4-triazole-3-carboxamide, and the hydrolysis product of this, 1,2,4-triazole-3-carboxylic acid. Ribavirin is not substantially incorporated into DNA, but does have a dose-dependent inhibiting effect on DNA synthesis, as well as having other effects on gene expression. Possibly for these reasons, significant teratogenic effects have been noted in all nonprimate animal species on which ribavirin has been tested. Ribavirin did not produce birth defects in baboons, but this should not be an indication that it is safe in humans. Therefore, two simultaneous forms of birth control are recommended during treatment of either partner and continued for 6 months after treatment. Women who are pregnant or planning to become pregnant are advised not to take ribavirin. Of special concern with regard to teratogenic risk is ribavirin's long half life in the body. RBCs concentrate the drug and are unable to excrete it, so this pool is not completely eliminated until all RBCs have turned over, a process estimated to take as long as 6 months. Thus, in theory, ribavirin might remain a reproductive hazard for as long as 6 months after a course of the drug has ended. Drug packaging information materials in the United States now reflect this warning [Seeff and Hoofnagle, 2002] .
Treatment of CHC infection
The fundamental goal for treating CHC infection is permanent eradication of the virus. Antiviral therapy inhibits virus production, decreases infection of new cells, and/or accelerates clearance of cells already infected. Even if the virus cannot be eradicated, treatment may slow disease progression and delay the complications of CHC infection [Seeff and Hoofnagle, 2002; Freeman et al. 2001 ]. The current standard treatment for CHC infection is the combination of PEG-IFN a and ribavirin. Although investigational treatments may modify, augment or eventually replace this standard, except for dosing variations, the standard has remained stable since 2001. The efficacy endpoint of hepatitis C treatment is the 'sustained virological response' (SVR), defined by the absence of detectable HCV RNA in serum as assessed by an HCV RNA assay with a lower limit of detection of 1000 copies/ml or less 6 months after the end of treatment.
Patients with detectable serum HCV RNA should be considered for PEG-IFN and ribavirin combination therapy. The decision to treat patients with CHC infection depends on multiple parameters, including a precise assessment of the severity of liver disease and of its foreseeable outcome, the presence of absolute or relative contraindications to therapy, and the patient's willingness to be treated.
Among the actions inherent in the natural proteins called IFNs are induction of an antiviral state in cells they target, secretion of cytokines, recruitment of immune cells and encouragement of cell differentiation. When IFN a is given subcutaneously, it binds specifically with highaffinity receptors present on most cell surfaces, including those of hepatocytes, producing two separate but complementary effects:
1. It establishes a nonspecific antiviral state in infected cells that inhibits viral replication. This may also occur in noninfected cells, diminishing their chances of becoming infected. IFN a also enhances the host's antiviral immune responses, possibly speeding the death of cells already infected with the virus. 2. It invokes a host of other effects when it binds to receptors of immune cells: it activates effector cells such as macrophages, natural killer cells, and cytotoxic T lymphocytes; it induces class I major histocompatibilitycomplex antigen expression; it and interacts intricately with the cytokine cascade [Caliceti, 2004; Youngster et al. 2002] .
Currently, IFN a is seldom used in the treatment of HCV without having first been pegylated to improve efficiency of the drug by increasing its systemic retention and possibly enhancing its binding affinity for cell receptors, which may speed absorption and alter distribution patterns.
The HCV genotype should be systematically determined before treatment, as it determines the indication, the duration of treatment, the dose of ribavirin and the virological monitoring procedure. Because the antiviral activity of IFN a is not thoroughly mapped, it is not known why the antiviral action of PEG-IFN a-2b is more effective in patients with genotype 2 and 3 infection than in the other genotypes. In addition, subtypes within each genotype vary in sensitivity to IFN a. It is encouraging to note, however, that treatment with neither PEG-IFN nor ribavirin appears to promote viral resistance.
Treatment for HCV genotype 1 infection
Given the likelihood of an SVR of the order of 4050%, a precise assessment of liver disease prognosis by means of a liver biopsy or a noninvasive method based on serological markers of fibrosis or ultrasound-based testing must be performed in order to help with the treatment decision. It is recommended not to treat patients with mild lesions and to reassess their liver disease after 35 years. The patients with inflammation and/or fibrosis (Metavir score A 2 and/or F 2) have an indication for therapy.
The approved dose of PEG-IFN a-2a is 180 mg per week, independent of body weight, whereas that of PEG-IFN a-2b is weight adjusted at 1.5 mg/kg per week, identical for all HCV genotypes. Patients infected with HCV genotype 1 should receive a high dose of ribavirin, i.e. 10001200 mg daily, based on bodyweight less than or greater than 75 kg. The heaviest patients could benefit from a higher ribavirin dose, up to 1600 mg daily. Genotype 1-infected patients theoretically require 48 weeks of treatment.
Monitoring of HCV RNA load decrease during therapy must be performed in order to avoid treating patients with no likelihood of a subsequent SVR. For this purpose, HCV RNA quantification must be performed at baseline and after 12 weeks of treatment. If HCV RNA is undetectable at week 24 (<1000 copies), treatment must be continued until week 48, with a high likelihood of an SVR. It was recently suggested that 24 weeks of therapy might be sufficient for patients with a low baseline viral load, a 2-log or more decline at week 12 and undetectable HCV RNA at week 24. Rapid virological responders, defined as patients with no detectable HCV RNA at week 4 of therapy, could also benefit from shorter therapy. Ongoing trials will feed future guidelines.
In contrast, if HCV RNA is still detectable at week 24, the likelihood of an SVR is virtually zero and treatment can be stopped or continued with the only aim to slow liver disease progression in patients with a severe prognosis, without any hope of eradicating infection. Ongoing trials are studying whether a prolonged antiviral treatment or maintenance therapy with PEG-IFN a monotherapy could be beneficial in these patients. When treatment is continued until week 48, the end of treatment and SVR should be assessed by means of a sensitive HCV RNA assay, with a lower limit of detection of 50 IU/ml or less. HCV RNA detection at the end of therapy is highly predictive of a posttreatment relapse (the more sensitive assays allow earlier identification of relapser patients), whereas the absence of HCV RNA at the end of treatment indicates a virological response. The latter patients must be retested for HCV RNA with a sensitive method 24 weeks later in order to assess the SVR, i.e. the endpoint of therapy. HCV infection appears to be definitively cured in the vast majority of sustained virological responders.
The lack of a 12-week virological response (no change or an HCV RNA decrease of less than 2-log at week 12) is associated with a virtually zero probability of a subsequent SVR. Treatment can thus be stopped at week 12 in these patients, or continued to slow liver disease progression without clearing the virus. The benefits of maintenance therapy on the outcome of HCV-associated liver disease are currently under investigation. This 'stopping rule', based on monitoring of HCV RNA load reduction at week 12, was recently shown to also apply to patients co-infected with HCV and human immunodeficiency virus [Huang and Hu, 2006; Pawlotsky, 2005] .
In a recent study, the efficacy and tolerability of PEG-IFN a-2a versus PEG-IFN a-2b were compared in a patient cohort with HCV-related active 0%) . This study demonstrated nonstatistically significant differences in effectiveness in patients nonresponsive to previous antiviral treatment [Scotto et al. 2008] .
Treatment for HCV genotype 2 or 3 infection
Patients infected with HCV genotypes 2 or 3 have a 7080% likelihood of an SVR with a low dose of ribavirin and only 24 weeks of treatment. Thus, in the absence of contraindications, these patients should be treated regardless of the severity of their liver disease. The recommended dose of PEG-IFN a-2a or a-2b is the same as for infection with genotype 1 HCV. The fixed recommended dose of ribavirin is 800 mg per day. It is possible that lower doses of ribavirin and/or shorter duration of treatment could be sufficient to achieve an SVR in certain subgroups of patients with genotype 2 or 3 infection, such as those with a low baseline viral load and no extensive fibrosis or cirrhosis, as suggested by recent preliminary data. One should be careful in patients who combine several baseline parameters of nonresponse, such as extensive fibrosis, older age and male gender, who might need 48 weeks of therapy to clear infection.
No monitoring of HCV RNA level changes during therapy is recommended in patients with genotype 2 or 3 infection, because the vast majority of them become HCV RNA negative early during treatment. Similar to treatment of HCV genotype 1-infected patients, the virological response must be assessed by means of a sensitive HCV RNA assay at the end of therapy and 24 weeks later in order to determine whether the virological response is sustained [Patel and McHutchison, 2003] .
Treatment for HCV genotype 4, 5 or 6 infection In the absence of any clinical trial including a sufficient number of patients, the likelihood of an SVR and the optimal treatment schedule remain unknown for patients infected with HCV genotypes 4, 5 or 6. It is thus recommended to treat them in the same way as those infected with genotype 1 HCV, i.e. with PEG-IFN a at the usual dose, combined with a high dose of ribavirin (10001200 mg/day, according to body weight less or greater than 75 kg). In the absence of published data, no stopping rules have been defined and it is recommended to treat these patients for a total of 48 weeks. The virological response must be assessed by means of a sensitive HCV RNA assay (lower limit of detection of 50 IU/mL or less) at the end of therapy and 24 weeks later [Strader et al. 2004] .
Special categories
Relapsers and nonresponders. Relapsers are patients in whom HCV RNA is negative at the end of therapy but later becomes positive. If such patients receive a course of the same therapy, the same result is probable; however, the chance of a SVR will increase if retreatment is pursued with better treatment. If the initial treatment was monotherapy, for example, then combination therapy should be used to retreat; if the initial therapy was with IFN and ribavirin, a trial with PEG-IFN and ribavirin should be considered. In general, for those who previously failed to respond to HCV treatment, retreatment with PEG-IFN and ribavirin may increase the frequency of response to 10% in previous nonresponders to standard IFN plus ribavirin, and to 20% in nonresponders to IFN monotherapy. Retreatment is less likely to help, or will improve responsiveness to a lesser extent, in patients with genotype 1 HCV infection, high baseline HCV RNA levels, cirrhosis and black ethnicity [Pawlotsky, 2005; Strader et al. 2004] .
Patients affected by cirrhosis. When treatment can be tolerated, patients with compensated cirrhosis can undergo antiviral therapy. Standard combination therapy can produce an SVR, but anaemia must be closely monitored.
A considerable population of patients has a predisposition to developing anaemia or complications of anaemia when treated with ribavirin. Patients with cirrhosis are at greatest risk of morbidity and mortality should HCV progress, and many of these patients, for numerous reasons, are already anaemic. Thus, when cirrhosis is decompensated, referral for liver transplantation may be the best option [Strader et al. 2004] . Haematologic disorders. Although data determining the safety and efficacy of ribavirin at any dose in people with haematologic disorders are limited (many trials of combination antiviral therapy specifically excluded them), chronic HCV in patients with many haematologic disorders can be treated with PEG-IFN a-2b plus ribavirin. Although PEG-IFN plus ribavirin therapy may be contraindicated in patients with thalassaemia and other haemoglobinopathies who have HCV from blood transfusions, researchers in a small pilot study recommended combination therapy for this population. There was a greater need for transfusions during therapy, probably because of ribavirin-related anaemia. In patients who have a genetic predisposition to anaemia, ribavirinassociated haemolysis and transfusion requirements are likely to be more drastic. Elderly patients, especially those with coronary artery disease, are often less able to tolerate anaemia, and treatment should be given only with caution. Patients with haemophilia and HCV are treated the same as the general population although biopsy may be deferred [Douglas, 2007; McHutchison et al. 2007 ].
Conclusions
For patients affected by CHC infection, the firstline therapy is combination of PEG-IFN a-2a or a-2b with ribavirin. Treatment must be started in patients with detectable serum HCV RNA. In patients infected by genotypes 1 or 4 before treatment, a histological evaluation is needed. These patients can be treated if stage is 2, according to the Knodell index. Treatment must be prolonged for 1 year and current guidelines allow continuing treatment if patients remain HCV RNA positive at week 12 if they have achieved a 2-log drop in viral load. In patients affected by genotypes 2 and 3, therapy must be prolonged for 6 months and histological evaluation pretreatment is not needed.
Recovered intravenous drug users, even those on methadone maintenance, can be treated with combination antiviral therapy as for other patients. CHC-infected patients with haemophilia are treated the same as the general population although biopsy may be deferred, while PEG-IFN plus ribavirin therapy may be contraindicated in patients with thalassaemia and other haemoglobinopathies. When treatment can be tolerated, patients with compensated cirrhosis can undergo antiviral therapy, while patients with decompensated cirrhosis may be referred for liver transplantation as the best option. Patients with end-stage renal disease should not be treated for HCV infection.
